Andrew Peter Sandham

Andrew Peter Sandham founded Cantab Pharmaceuticals Plc, Signature BioScience, Inc., Hexagen Plc, and Ionix Pharmaceuticals Ltd. Mr. Sandham also currently works at Predictimmune Ltd., as Chairman, Polyprox Therapeutics Ltd., as Executive Chairman from 2019, and Loqus23 Therapeutics Ltd., as Director from 2019.
Mr. Sandham also formerly worked at Kymab Ltd., as Chairman & Chief Executive Officer, Novacta Biosystems Ltd., as Chairman, NeurAxon, Inc., as Chairman, Bicycle Therapeutics Plc, as Chairman from 2011 to 2016, Ipsen Bioinnovation Ltd., as Chairman from 2010 to 2011, Synosia Therapeutics AG, as Director, Plant Bioscience Ltd., as Non-Executive Director, Celltech Group Plc, as Principal, GE Healthcare Ltd. (United Kingdom), as Principal, Abingworth Management, Inc., as Venture Partner, Roche Ltd., as Principal, and Syncona Partners LLP, as Partner from 2013 to 2015.
Mr. Sandham received his undergraduate degree from Norwich University, undergraduate degree from the University of East Anglia, and graduate degree from Chartered Institute of Personnel & Development.